Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 10;139(6):942-946.
doi: 10.1182/blood.2021013714.

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Soledad Henriquez  1 , Jérémie Zerbit  2 , Timothée Bruel  3   4 , Amani Ouedrani  5   6 , Delphine Planas  3   4 , Paul Deschamps  7 , Isabelle Staropoli  3 , Jérôme Hadjadj  1 , Bruno Varet  8 , Natalia Ermak  9 , Didier Bouscary  7   10 , Lise Willems  7 , Guillemette Fouquet  7 , Justine Decroocq  7 , Patricia Franchi  7 , Benedicte Deau-Fischer  7 , Benjamin Terrier  1   11 , Jérôme Tamburini  7   12 , Lucienne Chatenoud  5   6   13 , Olivier Schwartz  3   4 , Marguerite Vignon  7
Affiliations

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Soledad Henriquez et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Impaired humoral and cellular response to BNT162b2 in patients with MM. (A) Flowchart of the study. BNT162b2 anti–SARS-CoV-2 vaccine was used in this study; 2 doses were administrated 4 weeks apart. In all, 16 patients (from the anti-CD38 group) received a third booster vaccine dose. The anti-CD38 group is defined as patients who were treated with anti-CD38 immunotherapy. The convalescent group is defined as patients with a history of SARS-CoV-2 infection who were given the vaccine. T0 is the time before vaccine, M1 is 1 month after the first vaccine dose, and M3 is 3 months after the first vaccine dose. (B-C) SARS-CoV-2–specific IgG and IgA production quantified by S-Flow in 60 patients with MM who had never been infected with SARS-CoV-2 and 23 healthy volunteers. (B) IgG (left panel) and IgA (right panel) quantification in controls or patients with MM before vaccination (T0) and at M1 and M3. (C) Comparison of IgG amounts in patients with MM who were treated or not treated with anti-CD38 immunotherapy. (D-E) Quantification of anti-SARS-CoV-2 nAbs against alpha or delta variants in controls (n = 23) or patients with MM (n = 60). (D) Comparison between controls and patients with MM. (E) Comparison between patients receiving or not receiving anti-CD38 immunotherapy. (F) Quantification of cellular immune response by S1 or S2 EliSpot (in spot forming units, SFU, per 106 CD3 cells) in controls (n = 21) or patients with MM (n = 26). Patients receiving anti-CD38 immunotherapies are indicated. Error bars represent standard error. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, not significant.
Figure 2
Figure 2
Impact of SARS-CoV-2 infection on immunologic response to BNT162b2 in patients with MM. (A-C) Patients with MM with a history of infection with SARS-CoV-2 (more than 3 months before vaccination) who developed their infection at any time after vaccination or who had never had SARS-CoV-2 infection. (A) S-Flow IgG quantification (history of SARS-CoV-2 infection, n = 11; post-vaccine SARS-CoV-2, n = 4; other, n = 56). (B) Alpha (left) or delta (right) nAb quantification (history of SARS-CoV-2 infection, n = 11; post-vaccine SARS-CoV-2, n = 4; other, n = 56). (C) S1 (left) or S2 (right) IFN-γ EliSpot (SARS-CoV-2 history, n = 5; other, n = 21). Error bars represent standard error. *P < .05; ***P < .001; ****P < .0001. ns, not significant.
See this image and copyright information in PMC

References

    1. European Society for Medical Oncology,. ESMO Statements on vaccination against COVID-19 in people with cancer. https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination. Accessed 24 June 2021.
    1. Terpos E, Zagouri F, Liontos M, et al. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. J Hematol Oncol. 2021;14(1):86. - PMC - PubMed
    1. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature. 2021;596(7871):276–280. - PubMed
    1. Grzelak L, Temmam S, Planchais C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12(559):eabc3103. - PMC - PubMed
    1. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27(5):917–924. - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts